Please upgrade your browser.
According to a study that was done by the Asian Pacific Journal of Cancer Prevention, the overall survival rate of young adults (ages 18-40 years old) with localized renal masses is 93.8%.
As the treatment paradigm for metastatic renal cell carcinoma (mRCC) continues to evolve, combination therapy is likely to be an important part of the future, said Bradley G. Somer, MD.
Dr. Brian Rini and Dr. David McDermott explain whatâs next in kidney cancer research.
Bone metastases (BMs) are associated with significant morbidity and shorter survival in renal cell carcinoma (RCC). Our purpose was to identify prognostic factors for overall survival (OS) in RCC patients with BMs.
Treating metastatic kidney cancer with immediate cytoreductive nephrectomy (CN) did not ward off disease progression, the randomized SURTIME trial confirmed.
Life threatening toxicities of chemotherapies and immunosuppressants can occur with varying frequency depending on the agent suspected and underlying patient risk factors. It is important for clinicians to remember that these medications can be the cause or contributor to many important complications that occur in the ICU.
Economic Burden of Metastatic Clear-Cell Renal Cell Carcinoma for French Patients Treated With Targeted Therapies
Targeted therapies have transformed the treatment of metastatic clear-cell renal cell carcinoma (mccRCC). Despite the importance of mccRCC, studies on its economic burden in daily practice are sparse.
The most important prognostic factor when treating renal cell carcinoma (RCC) is tumor staging. Larger tumors (greater than 4 cm to 5 cm) need to be carefully assessed for the possibility of renal sinus invasion, according to a new review published Surgical Pathology Clinics.
Symptoms, risk factors and diagnosis of Kidney (Renal Cell) Cancer.
Updated clinical trial results reveal Tivozanib superior to Nexavar and headed to the FDA for US approval.
|Powered by NeonCRM|